Business / Finance

RSS

Materion fourth quarter sales down 6% to $334.4M

Materion Corporation today reported fourth quarter and full-year 2011 results. The Company also confirmed its outlook for a stronger 2012. The results for the quarter and the outlook are consistent with those announced on February 8, 2012.

27 Feb 2012

Opexa 2011 net loss increases to $5,968,448

Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2011 and provided an overview of corporate developments during the last year.

27 Feb 2012

Dendreon 2011 product revenue increases to $213.5M

Dendreon Corporation today reported results for the year and quarter ended December 31, 2011. Product revenue for the year ended December 31, 2011 was $213.5 million compared to $48 million for the year ended December 31, 2010. Product revenue for the fourth quarter of 2011 was $77 million compared to $25 million for the quarter ended December 31, 2010.

27 Feb 2012

Savient fourth quarter net loss increases to $30.9 million

Savient Pharmaceuticals, Inc. reported financial results for the three months ended December 31, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA(pegloticase). Savient ended the quarter with approximately $170 million in cash and short-term investments, a decrease of $33 million for the quarter.

27 Feb 2012

New research report on the electrosurgical devices market

ReportsnReports adds new market research report 'Electrosurgical Devices Market - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018' to its store. The global electrosurgical devices market is expected to reach $1,412.8m by 2018 growing at a CAGR of 5%.

27 Feb 2012

Roche extends cash tender offer to acquire all shares of Illumina

Roche announced today that it has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc., at a price of $44.50 per share, to 6:00 p.m., New York City time, on March 23, 2012.

From Illumina, Inc. 27 Feb 2012

Celldex announces pricing of underwritten public offering of common stock

Celldex Therapeutics, Inc. today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock, offered at a price to the public of $3.85 per share for an aggregate offering of $40,425,000 of common stock.

24 Feb 2012

Certara acquires Simcyp

Simcyp Limited announces its acquisition by Certara, a leading provider of drug discovery and development software and scientific consulting services.

24 Feb 2012

Standard Register fourth quarter revenue decreases to $161.4M

Standard Register today announced its financial results for the fourth quarter and full year 2011. The Company reported revenue of $161.4 million and a net loss of $95.5 million, or $3.28 per diluted share for the fourth quarter of 2011.

24 Feb 2012

SANUWAVE, CAN-med Healthcare enter distribution agreement for dermaPACE device

SANUWAVE Health, Inc. has entered into a two-year exclusive distribution agreement with CAN-med Healthcare, a division of IMP Group Limited, to distribute the Company's dermaPACE device throughout Canada.

24 Feb 2012

YM BioSciences prices 35,000,000 common shares in underwritten public offering

YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer related products, today announced the pricing of 35,000,000 common shares at US$2.00 per common share in its previously announced underwritten public offering.

24 Feb 2012

Endo fourth quarter total revenues increase 57% to $803.4 million

Endo Pharmaceuticals today reported financial results for the fourth quarter of 2011.

24 Feb 2012

Cyberonics third quarter net sales increase 16% to $54.5 million

Cyberonics, Inc. today announced results for the quarter ended January 27, 2012.

24 Feb 2012

Biofund, Quintiles to expand clinical development services in Russia

Russian Venture Company Biofund, a Russian-based investment firm, and Quintiles, the world's leading biopharmaceutical services company, today announced a definitive agreement to support expansion of clinical development services within the Russian Federation, the world's ninth most populous country.

24 Feb 2012

Western Dental Services celebrates expansion into Northern California

Western Dental Services, Inc., celebrates its continuing expansion into Northern California with a ribbon-cutting ceremony on Tuesday, February 28th, at its newest office in Livermore.

24 Feb 2012

Aerocrine net sales increase 10% to SEK 93.5m for January - December 2011

Aerocrine: January - December 2011. Global Net sales grew by 10% to SEK 93.5m (84.7). Adjusted for currency fluctuations, net sales rose by 18%.

24 Feb 2012

Sandvik reaches agreement with Orchid to sell medical solutions unit

Sandvik has reached an agreement with Orchid Orthopedic Solutions (Orchid), owned by Altor Fund III, to divest Sandvik Medical Solutions, a unit within the Sandvik Venture business area with contract manufacturing of medical implants and instruments for orthopaedic and dental applications.

24 Feb 2012